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Abstract
Bone marrow hematopoietic stem cells (HSCs) balance proliferation and differentiation by integrating complex
transcriptional and post-translational mechanisms regulated by cell intrinsic and extrinsic factors. We found that transcripts
of G0/G1 switch gene 2 (G0S2) are enriched in lineage
2 Sca-1
+ c-kit
+ (LSK) CD150
+ CD48
2 CD41
2 cells, a population highly
enriched for quiescent HSCs, whereas G0S2 expression is suppressed in dividing LSK CD150
+ CD48
2 cells. Gain-of-function
analyses using retroviral expression vectors in bone marrow cells showed that G0S2 localizes to the mitochondria,
endoplasmic reticulum, and early endosomes in hematopoietic cells. Co-transplantation of bone marrow cells transduced
with the control or G0S2 retrovirus led to increased chimerism of G0S2-overexpressing cells in femurs, although their
contribution to the blood was reduced. This finding was correlated with increased quiescence in G0S2-overexpressing HSCs
(LSK CD150
+ CD48
2) and progenitor cells (LS
2K). Conversely, silencing of endogenous G0S2 expression in bone marrow
cells increased blood chimerism upon transplantation and promoted HSC cell division, supporting an inhibitory role for
G0S2 in HSC proliferation. A proteomic study revealed that the hydrophobic domain of G0S2 interacts with a domain of
nucleolin that is rich in arginine-glycine-glycine repeats, which results in the retention of nucleolin in the cytosol. We
showed that this cytosolic retention of nucleolin occurs in resting, but not proliferating, wild-type LSK CD150
+ CD48
2 cells.
Collectively, we propose a novel model of HSC quiescence in which elevated G0S2 expression can sequester nucleolin in the
cytosol, precluding its pro-proliferation functions in the nucleolus.
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Introduction
Over an individual’s lifetime, the long-lived hematopoietic stem
cells (HSCs) are confronted with a number of different potential
fates: maintenance of the HSC pool (self-renewal), production of
blood cells on demand (differentiation), mobilization, death, or
entry into a reversible cell cycle arrest in which they remain poised
to re-enter cell division and differentiation (quiescence). A
balanced regulation of these processes ensures a continuous supply
of hematopoietic cells without leading to stem cell exhaustion or
bone marrow (BM) failure. The quiescent state preserves the
stemness of HSCs as well as their ability to efficiently reconstitute
ablated hosts upon transplantation. An emerging paradigm
suggests that quiescence is controlled by cell intrinsic factors (i.e.,
Bmi1, Mel18, Mll, ELF4, and c-myb) in addition to microenvi-
ronmental cues [1,2,3]. Despite its critical role in hematopoiesis,
the molecular regulation of quiescence remains a poorly un-
derstood process, particularly at the post-transcriptional level
[4,5]. Thus, a better understanding of the regulatory mechanisms
that control the proliferation and differentiation of HSCs will aid
in the development of new approaches to accelerate hematologic
recovery from treatment-induced cytopenia.
G0S2 is a basic protein with an ill-defined function that was first
identified in lectin-activated lymphocytes [6]. It has been
postulated that G0S2 regulates the G0/G1 phase of the cell cycle
by either releasing lymphocytes from quiescence (G0 to G1
transition) or by promoting proliferation (G1 to S phase transition)
[6,7]. Several reports have suggested that G0S2 is a multifaceted
protein with disparate functions related to proliferation, metabo-
lism, inflammation, and carcinogenesis. G0S2 induces the
differentiation of 3T3-L1 fibroblasts into adipocytes downstream
of the peroxisome-proliferator-activated receptor (PPAR) and
inhibits lipolysis by interacting with adipose triglyceride lipase
[8,9,10]. The fact that the G0S2 gene is epigenetically silenced in
head and neck cancers, squamous lung cancer, and cisplatin-
resistant cancer cells suggests a role in tumor formation and
chemoresistance [11,12]. However, transcriptome analyses
showed that G0S2 expression is elevated in endometriosis [13],
bronchial epithelial cells treated with retinoic acid [14], senescent
dermal fibroblasts [15], BM cells from patients with rheumatoid
arthritis [16], and peripheral mononuclear cells from patients with
vasculitis and psoriasis [17,18]. Interestingly, rheumatoid arthritis
and psoriasis patients displayed a low frequency of CD34-positive
cells in the peripheral blood and low counts of colony-forming cells
with high proliferative potential in the BM [19,20]. Although the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38280molecular basis of these findings has not yet been elucidated, they
suggest that elevated levels of G0S2 may correlate with inefficient
hematopoiesis.
Nucleolin is a multifunctional protein that is predominantly
localized to the nucleolus but is also detected in the nucleoplasm
and cytosol and at the cell surface [21]. Nucleolin indirectly
promotes cell growth by regulating the transcription of ribosomal
DNA in the nucleolus, maturation of pre-ribosomal RNA in the
nucleus, and transport of ribonucleoproteins and ribosomal
particles to the cytosol for final assembly [22]. In addition,
nucleolin stabilizes mRNA, enhances translation, and shuttles
proteins into the nucleus [23,24,25]. Nucleolin’s ability to increase
protein biosynthesis and cell mass suggests that this protein may
also help to control the cell cycle. In fact, rapidly dividing cancer
cells show increased nucleolin expression [26].
The role of G0S2 in the proliferation of hematopoietic cells has
not been investigated since its identification in lymphocytes [6]. In
this study, we show that ectopic expression of G0S2 increases the
percentage of lineage
2 Sca-1
+ c-kit
+ CD150
+ CD48
2 cells in the
G0 phase of the cell cycle and reduces blood chimerism in
competitive transplantation assays. We identified G0S2 protein
partners and found that the hydrophobic domain of G0S2
interacts with the arginine-glycine-glycine (RGG)-rich domain of
nucleolin, resulting in the cytosolic retention of nucleolin and
reduced proliferation of HSCs. We propose a new model in which
HSC quiescence is mediated by the elevated expression of G0S2
and sequestration of nucleolin in the cytosol.
Results
G0S2 is expressed in hematopoietic stem cells
We first measured G0S2 expression in purified HSCs, pro-
genitor cells, and mature cells by quantitative real-time PCR to
gain insight into its function in bone marrow hematopoiesis. G0S2
transcripts are enriched in two HSC populations: lineage
2 Sca-1
+
c-kit
+ (LSK) CD150
+ CD48
2 CD41
2 (LSK CD150
+ CD48
2
CD41
2) and LSK CD150
+ CD48
2 cells (Figure 1A). Interestingly,
low G0S2 expression was detected in MPP (LSK CD150
2 CD48
2
CD41
2), CMP (LS
2KF c cRII/III
lo CD34
+), GMP (LS
2K
FccRII/III
hi CD34
+), MEP (LS
2KF c cRII/III
2 CD34
2), and
mature myeloid and lymphoid cells (Figure 1A). These findings
suggested that G0S2 might play a role in the maintenance of
HSCs.
Because G0S2 is a G0/G1 switch gene, we induced HSC
proliferation in vivo by administering a single dose of 5-fluorouracil
(5-FU) to wild-type mice and then quantified G0S2 expression in
BM cells at different times during regenerative proliferation to
determine whether G0S2 regulates proliferation. Similar to BM
cellularity and in contrast to the expression of cyclin E2, G0S2
expression was rapidly downregulated in BM cells, with a nadir
occurring at day 6 after 5-FU injection (Figure 1B). This
suppression of G0S2 expression in proliferating hematopoietic
cells suggests an inhibitory role in cell division. To determine
whether this expression pattern could be attributed to HSCs, we
measured cyclin E2 and G0S2 expression in LSK CD150
+
CD48
2 cells purified from untreated (day 0) or 5-FU-treated (day
6) mice. As predicted, G0S2 expression was inversely correlated
with cyclin E2 expression in proliferating LSK CD150
+ CD48
2
cells (Figure 1C). Because LSK CD150
+ CD48
2 cells have been
used by several groups to immunophenotypically define HSCs
with long-term repopulating potential [27,28,29,30], these data
suggest that G0S2 has an inhibitory effect on HSC proliferation,
and its expression is therefore suppressed during regenerative
hematopoiesis.
Ectopic G0S2 expression reduces the contribution of
HSCs to the peripheral blood
We decided to study the effects of G0S2 in both in vitro and in
vivo hematopoiesis using a gain-of-function mouse model because
G0S2 was found to be upregulated in hematopoietic cells from
patients suffering from inflammatory disorders and presenting low
frequencies of primitive hematopoietic progenitor cells [19,20].
BM cells from 5-FU-treated C57BL/6 (B6) mice were transduced
with either MIGR1 V5-tagged G0S2 or empty MIGR1 retrovirus.
Ectopic G0S2 expression was confirmed in BM cells positive for
enhanced green fluorescent protein (EGFP) by quantitative real-
time PCR and immunoblotting (Figure 2A). We investigated the
subcellular localization of G0S2 in transduced BM cells by
immunofluorescence using anti-V5 antibodies and a panel of
antibodies that label different organelles. This analysis revealed
that G0S2 localizes to the area adjacent to the nuclear envelope
(Nup98) and also colocalizes with COX IV (mitochondria),
calnexin (endoplasmic reticulum) and Rab5 (early endosomes)
(Figure 2B). These findings are in accord with previous reports
indicating that G0S2 localizes to the endoplasmic reticulum and
mitochondria of 3T3-L1 and HeLa cells [8,31]. A distribution
among multiple cytosolic organelles suggests that G0S2 function in
hematopoietic cells may depend on its spatial expression pattern.
The difference in G0S2 expression between resting and
activated LSK CD150
+ CD48
2 cells indicates that G0S2 may
control proliferation in primitive hematopoietic progenitor cells.
An analysis of DNA content in BM cells transduced with MIGR1
or MIGR1-G0S2 revealed that G0S2 expression reduced the
percentage of BM cells in S phase (Figure 2C). Following BM
transplant, EGFP-positive BM cells were plated in methylcellulose
cultures to assess the capacity of hematopoietic progenitor cells to
generate myeloid colonies. No significant differences were
observed in the number of colony-forming units (CFUs) in
G0S2-overexpressing BM cells serially replated on methylcellulose,
indicating that forced G0S2 expression did not alter the initial
number of colony-forming cells and proliferation of more primitive
hematopoietic stem/progenitor cells (Figure 2D). However, the
number of cells recovered from each passage was significantly
lower in the G0S2-expressing BM cells because of a smaller size of
the colonies (Figure 2D), indicating that ectopic G0S2 expression
reduces the proliferation of colony-forming myelopoietic pro-
genitor cells. The use of cytokines in the methylcellulose cultures
with strong pro-proliferative function could overshadow differ-
ences in the proliferation at steady state.
Alterations in the proliferative capacity of G0S2-overexpressing
BM cells may affect their capacity to reconstitute ablated recipient
mice. We therefore transplanted BM cells transduced with either
the control or the V5-tagged G0S2 retrovirus (60% EGFP-positive
cells) into lethally irradiated mice to test the long-term hemato-
poietic reconstitution of multiple lineages. Donor-derived blood
cells were monitored in the peripheral blood by flow cytometry for
up to 6 months. Transplantation of G0S2-overexpressing BM cells
led to reduced blood chimerism, but the donor cells did contribute
to blood cell populations over the long-term (Figure 2E). In
addition, we found significant reductions in granulocytes (Gr-1
+
CD11b
+) and T cells (CD3
+) in mice transplanted with G0S2-
overexpressing BM cells (Figure 2E). The lower contribution of
G0S2-overexpressing BM cells to peripheral blood observed more
than 5 months post transplantation can likely be attributed to
a lower proliferative capacity of hematopoietic stem and pro-
genitor cells. To ensure that observed effects were due to sustained
G0S2 expression, we confirmed the expression by immunoblotting
in blood cells from chimeric mice 6 months after transplantation
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overexpression caused cell death in BM cells (Figure S1).
Although retroviral expression of G0S2 did not cause significant
apoptosis in hematopoietic cells, high levels of expression may
have nonspecifically altered cell proliferation and differentiation.
Therefore, it was important to also determine the effect of G0S2
loss-of-function in HSCs. We chose an shRNA-mediated method
to silence endogenous G0S2 expression in BM cells because mice
with a homozygous deletion of the G0S2 gene are not yet available.
Two G0S2-specific shRNA pSIREN retroviruses (Sh1 and Sh2)
were used to silence G0S2. A luciferase shRNA retrovirus (Luc)
was used as a control. The G0S2-specific shRNA retroviruses
reduced endogenous G0S2 expression in BM cells by 80% and
60% (Sh1 and Sh2, respectively) (Figure 3A). In contrast to the
overexpression results, G0S2 silencing increased the capacity of
HSCs to contribute to peripheral blood (Figure 3B). We also
observed that the extent of silencing was correlated with the
increase in percentages of Gr1
+ CD11b
+ and CD3
+ T cells,
particularly short-lived granulocytes, suggesting a dosage effect in
stem cell function (Figure 3C).
We further examined the effect of G0S2 overexpression on
HSCs by transplanting a 1:1 mixture of B6.SJL BM cells
(CD45.1
+) transduced with the MIGR1 retrovirus and B6 BM
cells (CD45.1
2) transduced with the MIGR1-G0S2 retrovirus into
B6 mice. Three months later, CD45.1 and EGFP expression levels
were monitored in the peripheral blood and BM by flow cytometry
to distinguish blood cells derived from control HSCs (MIGR1,
CD45.1
+ EGFP
+) and G0S2-overexpressing HSCs (MIGR1-
G0S2, CD45.1
2 EGFP
+). Surprisingly, the vast majority of blood
cells were derived from control HSCs, despite a clear pre-
dominance of G0S2-overexpressing cells in the BM (Figure 4A).
This result might be attributed to a combination of increased
homing to the BM upon transplantation (Figure S1) and lower
steady-state contributions to the blood caused by reduced
proliferation and/or differentiation.
G0S2 promotes quiescence in hematopoietic stem cells
To directly assess whether G0S2 inhibits HSC proliferation, we
purified LSK CD150
+ CD48
2 cells from chimeric mice
transplanted with either MIGR1-G0S2- or pSIREN-shG0S2-
Figure 1. G0S2 is expressed in dormant hematopoietic stem cells. (A) G0S2 transcripts were measured by quantitative real-time PCR in bone
marrow hematopoietic stem and progenitor cells based on SLAM markers and mature myeloid and lymphoid cells purified from the spleen (n=3).
Statistical significance is indicated between HSCs and progenitor cells (MPP, CMP, GMP, MEP). (B) Expression of G0S2 and cyclin E2 in BM cells isolated
at different times after administration of a single dose of 5-FU in C57BL/6 mice. The relative expression levels of G0S2 and cyclin E2 are shown as
percentages of basal levels (n=3–4). (C) Transcript levels of G0S2 and cyclin E2 were measured in LSK CD150
+ CD48
2 cells purified from untreated or
5-FU-treated (day 6) mice (n=3). The data represent the mean and standard deviation of each experiment. *, P,0.05 and **, P,0.01 (two-tailed
Student’s t-test).
doi:10.1371/journal.pone.0038280.g001
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by dual flow cytometric detection of Ki67 and 7-AAD, markers of
proliferation and DNA content, respectively. LSK CD150
+
CD48
2 cells negative for Ki67 with a 2n DNA content were
defined as ‘quiescent’ HSCs (G0 phase of the cell cycle).
Approximately 85% of wild-type LSK CD150
+ CD48
2 cells were
in the G0 phase of the cell cycle, emphasizing that this population
is highly enriched for dormant HSCs. Interestingly, ectopic
expression of G0S2 further increased the quiescence of LSK
CD150
+ CD48
2 cells (Figure 4B). As shown in Fig. 1, LSK
CD150
+ CD48
2 cells already express high levels of G0S2;
therefore, the increase in HSC quiescence observed upon G0S2
overexpression is relevant. This inhibition of the cell cycle was
consistent with the results of BrdU incorporation assays performed
in chimeric mice, where we observed a reduction in BrdU-positive
cells from 3366% (control) to 1761% (G0S2-overexpressing) in
primitive hematopoietic progenitor cells (not shown). Conversely,
G0S2 silencing in HSCs led to increased percentages of cells in the
G1 and S phases of the cell cycle (Figure 4C). In addition to HSC,
retroviral overexpression and silencing showed that G0S2 can also
modulate proliferation in LS
2K cells, a population enriched in
hematopoietic progenitor cells (Figure S2). From these experi-
ments, we concluded that G0S2 regulates the proliferation of
hematopoietic stem and progenitor cells.
Figure 2. Ectopic G0S2 expression reduces hematological reconstitution after BM transplantation. BM cells were transduced with
control MIGR1 or MIGR1-G0S2 (V5-tagged) retroviruses to study the effect of G0S2 on hematopoiesis. (A) Retroviral expression of G0S2 was measured
by quantitative real-time PCR and immunoblotting (n=3). (B) Transduced BM cells were used to study subcellular localization using anti-V5 (red),
DAPI (blue) and anti-Nup98, COX IV, Calnexin or Rab5 (green) antibodies. The data represent three independent experiments. (C) The cell-cycle
distribution of transduced BM cells was analyzed using nuclear staining with propidium iodine and flow cytometry (n=3). (D) Transduced BM cells
were transplanted into lethally irradiated mice and the frequency (CFU) and colony cell number were enumerated in methylcellulose culture (n=3)
after three months of hematologic reconstitution. (E) The contribution of donor-derived cells to myeloid and T cell populations in the peripheral
blood was analyzed after transplantation by flow cytometry at different times post-transplant (n=3–4). The data are representative of two
independent experiments. *, P,0.05, **, P,0.01, and ***, P,0.001 (two-tailed Student’s t-test).
doi:10.1371/journal.pone.0038280.g002
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Because G0S2 is a cytosolic protein with an unknown function,
we hypothesized that G0S2 may interact with proteins involved in
the control of cell division. To identify G0S2-interacting proteins
in hematopoietic cells, we transduced murine lymphoma EL4 cells
with the V5-tagged G0S2 retrovirus because the scarce number of
HSCs precluded a proteomic approach. First, we confirmed that
forced expression of G0S2 in EL4 cells reduced the percentage of
S-phase cells relative to the proportion observed in cells trans-
duced with an empty retrovirus (Figure S3). Next, cell lysates were
immunoprecipitated with an anti-V5 antibody, and immune
complexes were analyzed by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE). Proteins immunoprecipi-
tated with anti-V5 in the lysate of V5-tagged G0S2-expressing cells
but not control EL4 cells were excised from the gel and digested
with trypsin for peptide mass fingerprinting using mass spectrom-
etry. Four proteins with apparent molecular masses of 100, 47, 40,
and 30 kDa were identified as nucleolin and ribosomal proteins
L3, L6 and L13, respectively (Figure 5A). We focused on the
nucleolin interaction because of its known roles in ribosomal RNA
synthesis, chromatin remodeling, gene expression, and cell pro-
liferation [22]. We confirmed the interaction between G0S2 and
nucleolin in EL4 and BM cells by reciprocal co-immunoprecip-
itation using lysates from cells transduced with V5-tagged G0S2.
We demonstrated that the anti-V5 antibody co-immunoprecipi-
tated endogenous nucleolin and that the immunoprecipitation of
endogenous nucleolin resulted in the reciprocal immunoprecipi-
tation of V5-tagged G0S2 in lymphoblastic EL4 cells and, more
importantly, in murine BM cells (Figure 5B).
We next determined the domains responsible for the interaction
between G0S2 and nucleolin. G0S2 is a small, basic protein with
a central and highly conserved hydrophobic domain (HD) flanked
by N- and C-terminal domains (Figure 5C). We generated
retroviruses carrying mutants with deletions of the hydrophobic
domain (G0S2-DHD), the C-terminal and HD domains (G0S2
1–
26) or the N-terminal and HD domains (G0S2
43–103). Full-length
G0S2 interacted with nucleolin in NIH-3T3 cells, whereas the
G0S2
1–26, G0S2
43–103 and G0S2-DHD mutants did not
(Figure 5D). We then generated nucleolin mutants to determine
the domains required for G0S2 binding. The nucleolin (Ncl)
protein contains a cluster of 4 RNA-binding domains (RBDs) and
an arginine-glycine-glycine (RGG)-rich domain that binds ribo-
nucleoproteins. We generated the following nucleolin deletion
mutants (Figure 5E): Ncl
1–286 (the N-terminal domain, including
the nuclear localization signal), Ncl
287–707 (the C-terminal domain,
containing both the RBD and RGG-rich domains), Ncl-DRGG
(deletion of the RGG domain), and Ncl-DRBDs (deletion of all of
the RBD domains). NIH3T3 cells were co-transfected with an
expression vector containing a mutant or full-length nucleolin
protein and the V5-tagged G0S2 retroviral construct. Co-
immunoprecipitation assays showed that G0S2 only interacted
with the nucleolin mutants that contained the RGG domain: wild
type (Ncl-wt), Ncl
287–707, and Ncl-DRBDs (Figure 5F). From these
studies, we concluded that the hydrophobic domain of G0S2 binds
to the RGG domain of nucleolin.
The interaction between G0S2 and nucleolin leads to
cytosolic retention of nucleolin and cell cycle inhibition
in HSCs
We hypothesized that the interaction between G0S2 and
nucleolin might affect the proliferation of hematopoietic cells.
We transfected NIH3T3 cells with full-length or G0S2 mutants
and then measured the cell cycle distribution. Expression of wild-
type G0S2 reduced the percentage of cells in S phase; in contrast,
the DNA contents of the G0S2 mutants that failed to interact with
nucleolin were similar to those of the controls (Figure 6A).
Intriguingly, G0S2-overexpressing cells showed a perinuclear
distribution of nucleolin rather than the typical nucleolar
localization observed in control cells (Figure 6B). Conversely, cells
transfected with the G0S2-DHD, G0S2
1–26 or G0S2
43–103
construct showed a nucleolar localization of nucleolin, likely due
to the inability of the mutant proteins to interact with nucleolin via
the HD domain (Figure 6B).
The proteomic identification of G0S2 protein partners was
performed using EL4 cells, whereas the molecular interaction
assays were performed using fibroblasts. To correlate these
findings with those related to HSC proliferation, we examined
whether the G0S2-nucleolin interaction occurs in quiescent but
not proliferating HSCs. We first examined the localization of
nucleolin in HSCs purified from mice transplanted with MIGR1-
G0S2-V5 BM cells. Similar to the findings in cell lines,
endogenous nucleolin co-localized with the overexpressed G0S2-
V5 tagged protein around nuclei in LSK CD150
+ CD48
2 cells
(Figure 7A). Because the majority of LSK CD150
+ CD48
2 cells
are in G0, this perinuclear distribution of nucleolin in G0S2-
overexpressing HSCs suggests that cytosolic retention of nucleolin
might cause a reduction in stem cell proliferation. Remarkably,
endogenous nucleolin presented the same ring-like distribution in
wild-type LSK CD150
+ CD48
2 cells, whereas it was restricted to
Figure 3. Silencing of endogenous G0S2 expression in BM cells
increases blood chimerism upon transplantation. Expression of
the endogenous G0S2 gene was silenced in BM cells using two G0S2-
specific pSIREN-shRNA retroviruses (Sh1, Sh2). Luciferase pSIREN-shRNA
(Luc) was used as a control. (A) Knockdown efficiency was determined
by quantitative real-time PCR in transduced BM cells (n=4). (B) Sixteen
weeks after transplantation, blood chimerism was measured by flow
cytometry (n=3–4). (C) The contribution of donor-derived cells to the
Gr-1
+ CD11b
+ and CD3
+ T cell populations was analyzed at different
times after the transplant (n=3–4). *, P,0.05, **, P,0.01, and ***,
P,0.001 (two-tailed Student’s t-test).
doi:10.1371/journal.pone.0038280.g003
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+ LS
2K progenitor cells (Figures 7B and S3).
We next isolated LSK CD150
+ CD48
2 cells from mice injected 6
days before with 5-FU to induce cytoablation and regenerative
HSC proliferation. In proliferating HSCs, nucleolin was pre-
dominantly localized to the nucleoli, similar to proliferating
progenitor cells (Figures 7B and S3). Nucleolar localization in
cycling stem and progenitor cells correlated with low G0S2 levels
(Figure 1C). Collectively, our data show that increased levels of
G0S2 in nonproliferative HSCs induce cytosolic retention of
nucleolin, preventing nuclear shuttling and regulation of cell
division.
Discussion
The functional longevity of HSCs relies on their ability to
balance proliferation, differentiation, and quiescence. Stem-cell
intrinsic activators of quiescence can prevent the loss of stemness
by modulating responses to differentiation-inducing signals. In this
study, we found that G0S2 restricts the steady-state number of
HSCs entering the cell cycle in a cell-autonomous manner.
Furthermore, we showed that elevated levels of G0S2 in HSCs
cause retention of nucleolin in the cytosol and inhibition of cell
proliferation.
The initial finding that G0S2 expression is inversely correlated
with cyclin E2 levels in LSK CD150
+ CD48
2 cells, a population
highly enriched for HSCs [27,28,29,30], suggested that G0S2 may
be involved in the maintenance of stem cell quiescence.
Competitive BM transplants revealed that HSCs overexpressing
G0S2 were able to contribute to the hematopoietic system over the
long term, although with lower efficiency than wild-type HSCs.
Conversely, retroviral silencing of the endogenous G0S2 gene in
BM cells resulted in increased contributions to the peripheral
myeloid and lymphoid cell populations upon transplantation. We
hypothesized that G0S2 primarily regulates the decision to
proliferate or remain quiescent in HSCs: ectopic G0S2 expression
led to an increased percentage of quiescent HSCs, whereas
silencing resulted in increased HSC proliferation. We also
observed that G0S2 modulates at some extent the proliferation
of hematopoietic progenitor cells although myeloid committed
progenitor cells appear to be less dependent on G0S2 regulation.
Consistent with increased homing of quiescent HSCs [32], ectopic
G0S2 expression led to increased chimerism in the BM but
Figure 4. G0S2 enhances the quiescence of hematopoietic stem cells. (A) To analyze the reconstitution potential of G0S2-overexpressing BM
cells relative to wild-type BM cells, we performed a competitive transplantation with a mixture of BM cells transduced with the MIGR1 or MIGR1-G0S2
retrovirus (n=5). EGFP
+ CD45.1
+ and EGFP
+ CD45.1
2 cells were derived from MIGR1 and MIGR1-G0S2 BM cells, respectively. The data represent two
independent experiments. (B) The role of G0S2 in HSC quiescence was examined using a gain-of-function model. Flow cytometric analyses of Ki67
and 7-AAD were performed in LSK CD150
+ CD48
2 cells purified from chimeric mice transplanted with cells containing the control or G0S2 retrovirus
(n=3–4). Quiescent HSCs were defined as Ki67-negative cells (G0) with a 2n DNA content. (C) Flow cytometric analyses of Ki67 and 7-AAD were
performed in LSK CD150
+ CD48
2 cells purified from mice transplanted with G0S2-shRNA or the control retrovirus (n=4–5). *, P,0.05 and **, P,0.01
(two-tailed Student’s t-test).
doi:10.1371/journal.pone.0038280.g004
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result is more likely attributable to reduced HSC proliferation than
decreased differentiation because no differences were observed in
the number of myeloid colonies in clonogenic assays. In support of
our findings, a gene expression analysis in fibroblasts subjected to
prolonged quiescence revealed that upregulation of G0S2 was part
of a gene signature that suppresses proliferation [33].
Other factors known to induce HSC quiescence are p21, Gfi1,
Pten, and FoxO1, 3 and 4 [34,35,36,37]. Knockout mice deficient
in these factors showed increased homeostatic cycling of HSCs and
eventual stem cell exhaustion, although augmented HSC pro-
liferation does not always cause a loss of stem cell function
[38,39,40]. For instance, overexpression of HoxB4 uncouples cell
division from differentiation in HSCs, leading to ex vivo HSC
expansion [39]. Our data suggest that modulations of G0S2
expression might be applied to preserve HSC stemness during ex
vivo culture, without the side effect of promoting differentiating cell
division events that might compromise long-term stem cell
Figure 5. The hydrophobic domain of G0S2 interacts with the RGG domain of nucleolin. Co-immunoprecipitation and proteomic analyses
were used to identify G0S2 protein partners. (A) G0S2-interacting proteins were pulled down with anti-V5 antibody in EL4 cells transduced with the
empty or G0S2-V5 tagged retrovirus. Bands from a SDS-PAGE gel stained with Coomassie Blue were cut out for identification by mass spectrometry.
(B) Reciprocal co-immunoprecipitation of V5-tagged G0S2 and nucleolin in EL4 and BM cells transduced with the MIGR1 (Ctrl) or MIGR1-G0S2 (G0S2)
retrovirus. (C) Diagram depicting the domains in the wild-type G0S2 protein and the deletion mutants G0S2-DHD, G0S2
1–26 and G0S2
43–103. (D) The
interaction between endogenous nucleolin and ectopic V5-tagged G0S2 was analyzed in NIH3T3 cells transduced with the empty retrovirus (Ctrl) or
retroviruses bearing wild-type G0S2 (G0S2-wt) or G0S2 mutant constructs (G0S2-DHD, G0S2
1–26 and G0S2
43–103). (E) Diagram depicting the domains
of the wild-type nucleolin (Ncl) protein and the deletion mutants Ncl
1–286, Ncl
287–707, Ncl-DRGG and Ncl-DRBDs (FLAG-tagged). RGG, arginine-glycine-
glycine-rich domain; RBD, RNA-binding domain. (F) Interactions between V5-tagged G0S2 and FLAG-tagged nucleolin constructs (Ncl-wt, Ncl
1–286,
Ncl
287–707, Ncl-DRGG and Ncl-DRBDs). The data represent two independent experiments.
doi:10.1371/journal.pone.0038280.g005
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scription factors that regulate G0S2 expression in HSCs are largely
unknown. The only activator of G0S2 described in hematopoietic
cells is retinoic acid [41]. Interestingly, retinoic acid treatment
enhances ex vivo maintenance of HSCs [42]. Similar to G0S2,
Stat5 activity promotes HSC quiescence [43], raising the
possibility that G0S2 could be regulated downstream of c-kit
and Mpl signaling. However, inhibition of calcium-dependent
calcineurin with cyclosporin A suppresses G0S2 transcription in
human blood mononuclear cells [7], and deletion of calmodulin-
dependent protein kinase IV resulted in hematopoietic failure due
to a numeric and functional reduction of HSCs [44]. Future
studies are required to define the regulation of G0S2 expression in
HSCs.
The cytosolic localization of G0S2 suggested that the G0S2-
mediated inhibition of HSC proliferation likely comprises a non-
transcriptional mechanism involving protein-protein interactions.
In a proteomic analysis, we identified nucleolin as a new protein
partner of G0S2 and further showed that the hydrophobic domain
of G0S2 is required for this interaction. Nucleolin is a phospho-
nucleolar protein involved in several phases of ribosome bio-
synthesis: transcription of ribosomal DNA in nucleoli, maturation
of pre-ribosomal RNA, and transport of ribonucleoproteins and
pre-ribosomal particles for ribosome assembly of ribosomes in the
cytosol [22,45,46]. However, the role of nucleolin in the HSC
proliferation has not been well studied, although nucleolin’s
function is generally thought to be associated to cell growth and
cell division. Nucleolin expression is elevated in rapidly dividing
cells and tumor cells, supporting a role for this protein in cell
proliferation [26]. Conversely, silencing of nucleolin expression in
HeLa cells and human fibroblasts reduced both the percentage of
cells in S phase and cell growth [47]. In hematopoietic cells,
retinoblastoma protein antagonizes the nucleolin-mediated acti-
vation of the CD34 promoter in KG1 acute myelogenous
leukemia cells [48]. Finally, nucleolin may contribute to the
IFNa-mediated release of HSCs from quiescence due to its ability
to transport Stat1 proteins into the nucleus [49,50]. Therefore,
G0S2 might modulate proliferation by interfering with the pro-
proliferation functions of nucleolin. In addition to nucleolin, we
also determined that ribonucleoproteins L3, L6, and L13 bind to
G0S2. Several ribosomal proteins, including L3, L6 and L13,
interact with nucleolin via the RGG domain in the C-terminal
moiety [51]. The fact that nucleolin also binds to the ribonucleo-
proteins found in our screen of G0S2-interacting proteins indicates
that G0S2 either binds directly to the RGG domain or to
a complex containing ribonucleoproteins and nucleolin.
Our overexpression study suggests that G0S2 interacts with
nucleolin when its cellular level reaches a certain threshold. This
interaction leads to the retention of nucleolin in the cytosol and
suppression of cell division. In support of the physiological
relevance of our findings, we demonstrated that wild-type LSK
CD150
+ CD48
2 cells, a population with high levels of endogenous
G0S2 gene expression, displayed a perinuclear distribution of
nucleolin. In contrast to the predominantly ‘ring-like’ distribution
observed in HSCs, progenitor cells (LS
2K) showed both peri-
nuclear and nucleolar localization of nucleolin, suggesting a lower
dependency on the G0S2 and Nucleolin interaction. This
difference might be related to the levels of G0S2 expression in
stem versus progenitor cells. The ring-like extranuclear distribu-
tion of nucleolin was previously described in nonproliferating
leukemic cells of chronic lymphocytic leukemia patients [24].
Similarly, T lymphocytes from HIV-positive patients show
a cytosolic expression of nucleolin that is not observed in healthy
donors [52]; however, this subcellular localization is associated
with apoptosis in CD4 T cells. Our work is the first report to
describe a mechanism for the subcellular redistribution of
nucleolin and the association of G0S2 with proliferation in
hematopoietic cells.
Most research in the field has focused on identifying the
transcriptional machinery that controls stem cell proliferation. Our
work supports a novel role for G0S2 in the regulation of nucleolin
function by its sequestration of nucleolin in the cytosol in quiescent
HSCs. This mechanism could potentially be targeted to reduce
cell-cycle-dependent cytotoxicity and improve engraftment in
bone marrow transplants.
Material and Methods
Mice
C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice were purchased
from Jackson Laboratories. All mice were bred and maintained
under specific pathogen-free conditions at the Baylor College of
Medicine. Chemical cytoablation was used to study hematological
recovery by intraperitoneal administration of a single dose of 5-
fluorouracil (5-FU) at a dose of 150 mg/kg. All experiments were
performed with the approval of the Institutional Animal Care and
Usage Committee of Baylor College of Medicine.
Figure 6. Inhibition of cell proliferation by G0S2 correlates with
cytosolic retention of nucleolin. (A) The effects of G0S2 deletion
mutants on the proliferation of NIH-3T3 cells were examined by
propidium iodine staining and flow cytometric analysis (n=3). G0S2-wt
was compared to G0S2 mutants and empty vector (Ctrl). *, P,0.05 (two-
tailed Student’s t-test). (B) Subcellular localization of endogenous
nucleolin was determined by immunofluorescence in NIH3T3 cells
transduced with the retrovirus containing full-length G0S2 or the
deletion mutants described in Figure 5. The inset shows a higher
magnification of a cell presenting nucleolar versus perinuclear
localization. The data represent two independent experiments.
doi:10.1371/journal.pone.0038280.g006
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NIH3T3 and EL4 cells were obtained from the ATCC.
NIH3T3 cells were cultured in DMEM (Lonza) containing 10%
(vol/vol) FBS. EL4 cells were cultured in RPMI medium (Lonza)
containing 10% (vol/vol) FBS.
Retroviral transduction
Murine G0S2-V5 tagged cDNA was cloned into the MIGR1
retroviral vector [53]. The luciferase-specific shRNA retroviral
construct (pSIREN-Luc) was purchased from Clontech and two
G0S2-specific shRNA (pSIREN-sh1 and pSIREN-sh2) retroviral
vectors were generated to induce G0S2 gene silencing. The G0S2
shRNA sequences were as follows: mouse sh1, 59-CGAGCAAT-
CAA GGAGCTAT-39; mouse sh2, 59-GAGTCA-
CATGCTGTTTCAA-39. HEK 293T cells were cotransfected
with a plasmid containing the retroviral vectorand y–ecotropic
envelope. After 2 days of transfection, supernatant containing
retrovirus was passed through a 0.4 mm filter before transduction.
BM cells were flushed out from the femur and tibias of mice
previously treated with 5-FU (150 mg/Kg) and cultured for two
days in the presence of stem cell factor (100 ng/ml, Peprotech), IL-
3 (6 ng/ml, Petrotech) and IL-6 (10 ng/ml, Peprotech) in X-vivo
15 medium (Lonza). Cells were then transduced twice by
spinoculation (60 min at 456 RCF) in the presence of polybrene
(8 mg/ml). Next, 1610
6 BM cells were injected intravenously into
the lateral tail vein of recipient mice that were previously
irradiated with 950 Rad. NIH3T3 cells were transduced with
retroviral supernatant in the presence of 8 mg/ml polybrene. EL4
cells were cocultured with packaging 293 T cells for 2 days,
followed by purification of EGFP-positive, nonadherent cells by
cell sorting.
Flow cytometry and cell purification
BM cells were flushed out from their tibias and femurs, and
hematopoietic progenitors were purified by lineage depletion using
the BD-IMag magnetic-bead separation system (BD Biosciences)
following the manufacturer’s instructions. Splenocytes were
filtered through 40 mm nylon cell strainer (BD Biosciences) to
obtain single-suspension cells. Blood samples were treated with
a hypotonic reagent for a lysis of red blood cells before staining.
The following antibodies were used to stain peripheral blood and
BM cells with the retroviral transduction: PE-Cy7-anti-CD11b
(BD Biosciences), APC-anti-Gr-1 (BD Biosciences), APC-anti-
CD3(BD Biosciences), PE-Cy7-anti-CD19 (BD Biosciences), APC-
anti-CD45.1 (eBioscience). Samples were analyzed by flow
cytometry using a FACSCanto instrument (BD Biosciences), and
the resultant data were analyzed using FlowJo software (Tree Star).
For isolation of LSK CD150
+ CD48
2 CD41
2 and LSK
CD150
+ CD48
2 HSCs, LSK CD150
2 CD48
2 CD41
2,F c cRII/
III
lo CD34
+,F c cRII/III
hi CD34
+,F c cRII/III
2 CD34
2, CD3
+
CD4
+, CD3
+ CD8
+, and CD19
+ cells, we used the following
antibodies: PE- or APC-anti-CD150 (BioLegend), FITC- or anti-
CD48 (BioLegend) or PE-Cy7-anti-CD48 (eBioscience), FITC-
anti-CD41 (BD Biosciences), PerCP/Cy5.5-anti-Sca-1 (BD Bios-
ciences) or FITC-Sca-1(BioLegend), APC-anti-c-kit (BD Bios-
ciences) or PE-Cy7-anti-c-kit (BioLegend), FITC-anti-CD16/32
(=FccRII/III) (BioLegend), APC-anti-CD34 (BioLegend), PE-
anti-CD11b (BD Biosciences), APC-anti-Gr-1(BD Biosciences),
APC-anti-CD3(BD Biosciences), FITC-anti-CD4 (BD Bios-
Figure 7. Quiescent HSCs exhibit cytosolic sequestration of nucleolin. (A) Nucleolin colocalizes with the overexpressed G0S2 protein in LSK
CD150
+ CD48
2 cells purified from mice transplanted with BM cells transduced with the MIGR1-G0S2 V5-tagged retrovirus. (B) Expression of nucleolin
and Ki67 was determined in wild-type LS
2K (proliferative progenitors), LSK CD150
+ CD48
2 cells purified from wild-type mice (dormant HSCs), and LSK
CD150
+ CD48
2 cells purified from wild-type mice injected 6 days earlier with a single dose of 5-FU (proliferative HSCs). Images of DAPI, nucleolin, and
Ki67 staining are shown for a representative cell. The data represent two independent experiments.
doi:10.1371/journal.pone.0038280.g007
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Biosciences). Cells were sorted using a MoFlo cell sorter
(Cytomation).
Cell cycle analysis
Purified EGFP-positive BM cells and NIH3T3 cells were
centrifuged and resuspended in a hypotonic buffer (0.1% sodium
citrate and 0.1% Triton X-100) containing 100 mg/ml RNase A
and 50 mg/ml propidium iodide. Samples were analyzed using the
FACScanto flow cytometer (BD Biosciences), and cellular DNA
content were analyzed using the ModFit software (Verity). Purified
EGFP-positive or ZsGreen-positive Lin
2 Sca-1
+ c-kit
+ CD150
+
CD48
2 (LSK CD150
+ CD48
2) HSCs and Lin
2 Sca-1
2 c-kit
+
progenitors from BM were fixed in 70% ethanol for 16 h and
stained with APC-anti-Ki67 (eBioscience) and 7-AAD (BD
Biosciences). Samples were analyzed using the FACScanto flow
cytometer and FlowJo software (Tree Star).
Real-time quantitative PCR
Total RNA was extracted using the RNeasy Mini kit or RNeasy
Plus Micro kit (Qiagen), and cDNA was then synthesized from
RNA using the SuperScript III kit (Invitrogen) with random
hexamer primers. Real-time PCR was performed using the
LightCycler FastStart DNA Master SYBR Green I (Roche).
Primer sequences for PCR were as follows: mouse b-actin forward,
59-GTGGGCCGCTCTAGGCACCA-39, and reverse, 59-
CGGTTGGCCTTAG GGTTCAGGGG-39; mouse G0S2 for-
ward, 59-GTGCTCGGCCTAGTTGAGAC-39, and reverse, 59-
CACCTGGGTCATGATCTGTG-39; mouse Cyclin E2 forward,
59-AGGAATCAGCCCTTGCAT TATC-39, and reverse, 59-
CCCAGCTTAAATCTGGCAGAG-39. Real-time PCR was
performed using the Mx3005P instrument (Stratagene, La Jolla,
CA) with denaturation at 95uC for 10 min followed by 40 cycles of
a 3-step PCR program consisting of 95uC for 15 sec, 55uC for
30 sec and 72uC for 30 sec. Gene expression was normalized to b-
actin levels (1610
4 copies).
Co-immunoprecipitation and immunoblot
EL4 cells, BM cells and NIH3T3 cells were transduced with
retroviruses, MIGR1 or MIGR1-G0S2. NIH3T3 cells were
cotransfected with plasmids for V5-tagged G0S2 and FLAG-
tagged nucleolin expression using Lipofectamine 2000 (Invitro-
gen). After 48 h, cells were lysed with a solution of 150 mM NaCl,
50 mM Tris pH 8, and 1% Triton X-100 containing a protease
inhibitor cocktail (Calbiochem). Cell lysate was immunoprecipi-
tated with Protein G-sepharose (Invitrogen) and mouse anti-V5
antibody (Invitrogen), rabbit anti-Nucleolin antibody (Abcam) or
rabbit anti-FLAG antibody (Cell Signaling technology). The
samples were then loaded onto NuPAGE Bis-Tris gels (Invitro-
gen), separated by electrophoresis, and transferred onto poly-
vinylidene difluoride membranes (Millipore) for immunoblot
analysis. Goat anti-rabbit IgG or goat anti-mouse IgG conjugated
to peroxidase (GE Healthcare) was used as a secondary antibody.
The chemiluminescent signals were gained with SuperSignal
substrate (Thermo Scientific). The bands were analyzed using the
FluorChemHD2 Chemi-Imager (Alpha Innotech, Santa Clara,
CA).
Mass spectrometry analysis
EL4 cells were transduced with retroviruses and lysed as
described above for co-immunoprecipitation. Cell lysates were
immunoprecipitated with Protein G-sepharose and anti-V5
antibody (Invitrogen). The immunoprecipitated proteins were
then resolved on NuPAGE Bis-Tris gels (Invitrogen) and stained
with Coomassie Blue R-250 (Fluka). Stained gel bands were
dehydrated and trypsinized, and the peptides were then analyzed
using an ABI/SCIEX 4700 Proteomic Analyzer TOF/TOF mass
spectrometer (The Proteomic Core Facility at Baylor College of
Medicine). Peptide mass fingerprinting was then analyzed using
MS-Fit and protein database searches.
Methylcellulose culture
BM cells were transduced with retroviral vectors (MIGR1 or
MIGR1-G0S2) and transplanted into irradiated mice. After two
months of hematologic reconstitution, 2610
4 EGFP
+ BM cells
were cultured in 6-well plates with methylcellulose medium
(MethoCult GFM3434, StemCell Technologies) to enumerate
myelopoietic progenitor cells. After 9–10 days, colonies were
enumerated, and each well was then resuspended for total cell
count. For serial replating, isolated 2610
4 cells were replated on
methylcellulose.
Generation of deletion mutants
Full-length murine G0S2 cDNA was cloned into the MIGR1
retroviral vector MIGR1 with a V5-tag and pcDNA3.1/V5-His A
(Invitrogen). G0S2 deletion mutants were generated by PCR using
the following primers, designed to generate deletion mutants
G0S2
1–26 (N-terminal) and G0S2
43–103 (C-terminal), respectively:
G0S2-N forward, 59-ATGGAAAGTGTGCAG-39; G0S2-N re-
verse, 59-TAGCTTCACTAGCTTCC-39; G0S2-C forward, 59-
GCCACCATGGTTGAGACGGTGTGCAG-39; and G0S2-C
reverse, 59-AGAGGCGTGCTGCCGGA-39. For the G0S2-
DHD, G0S2
1–26 and G0S2
43–103 mutants, PCR products were
combined using the following primers: G0S2-N/C sense, 59-
AAGCTAGTGAAGCTAGTTG AGACGGTGTGC-39, and
G0S2-N/C antisense, 59-GCACACCGTCTCAACTAGCTT-
CACTAGCTT-39. The full-length cDNA of murine nucleolin
was cloned into the p3XFLAG-Myc-CMV-24 expression vector
(Sigma). Nucleolin (Ncl) deletion mutants were generated by PCR
amplification using the following primers, designed to generate the
deletion mutants Ncl
1–286, Ncl
287–707, Ncl-DRGG, respectively:
Ncl-N forward, 59-TTTGAATTCTATGGTGAAGCTCG-
CAAAG-39; Ncl-N reverse, 59-
TTTGAATTCTCTCCTTCTTCCGTTTTCCAG-39; Ncl-C
forward, 59- TTTGAATTCTATGACCAAGCAGAAAGAAG-
39; Ncl-C reverse, 59- TTTGAATTCTTT-
CAAACTTCGTCTTCTTTCC-39; Ncl-DRGG forward, 59-
TTTGAATTCTATGGTGAAGCTCGCAAAG-39; and Ncl-
DRGG reverse, 59-TTTGAATTCTGGCCTCCTTGG-
CAGCTTTG-39. For the Ncl-DRBD mutants, the Ncl
1–286 and
Ncl
627–707 fragments were generated first using the following
primers: Ncl-N9 forward, 59-TTTGAATTCTATGGT-
GAAGCTCGCAAAG-39; Ncl-N9 reverse, 59-
GTCAATTTCTCCATCTTC-
CATCTCCTTCTTCCGTTTTCCAG-39; Ncl-RGG forward,
59- CTGGAAAACGGAAGAAGGAGATGGAAGATGGA-
GAAATTGAC-39; Ncl-RGG reverse, 59- TTTGAATTCTTT-
CAAACTTCGTCTTCTTTCC-39. Finally, Ncl
1–286 and Ncl
627–
707 were combined by using the primers Ncl-N9 forward and Ncl-
RGG reverse.
Immunofluorescence detection
LSK CD150
+ CD48
2 HSCs and lineage
2 Sca-1
2 c-kit
+
(LS
2K) progenitors were purified by cell sorting of BM cells
collected from non-transplanted or transplanted mice two months
prior with transduced MIGR1 or MIGR1-G0S2 BM cells.
Suspension cells were spun onto glass slides (Thermo) and
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prestained fluorescence. NIH3T3 cells were cultured in 8-well
culture slides (BD Biosciences) and fixed with 1% paraformalde-
hyde and permiabilized with 0.1% (vol/vol) Triton X-100. The
slides were stained with mouse anti-V5 and mouse-specific
antibody conjugated to Alexa Fluor 555 (Invitrogen). Subcellular
colocalization was determined using an antibody kit (Cell
Signaling Technology), anti-COX IV (Abcam), anti-calnexin
(Abcam), and a rabbit-specific antibody conjugated to Alexa Fluor
488. Nucleolin was detected by rabbit anti-nucleolin (Abcam) and
a rabbit-specific antibody conjugated to Alexa Fluor 488 or Alexa
Fluor 555 (Invitrogen). Ki67 was stained with FITC-anti-Ki67
(Vector Laboratories). The slides were mounted with a mounting
solution containing 49-6-diamidino-2-phenylindole (DAPI) (Invi-
trogen) and analyzed on the microscope Eclipse 90i (Nikon) and
the imaging software NIS Elements (Nikon).
Bone marrow homing assay
BM cells were harvested from 5-FU treated mice and trans-
duced with either MIGR1-G0S2 or MIGR1 empty retrovirus.
Twenty-four hours later, EGFP-positive cells were purified by cell
sorting and injected (1610
5 cells) into the tail veins of irradiated
recipient mice. BM cells were isolated from the mouse femurs 15 h
later to determine the percentage of EGFP-positive cells by flow
cytometry.
Statistical analysis
Significant differences were determined using a two-tailed
Student’s t-test (GraphPad solftware). A p value of ,0.05 was
considered significant. Statistics are indicated in each figure
legend.
Supporting Information
Figure S1 Ectopic expression of G0S2 enhances homing
of BM cells without inducing apoptosis. (A) The profile of
Annexin V and 7-AAD is shown for gated EGFP+ BM cells
transduced with MIGR1 or MIGR1-G0S2 retrovirus (n=3). (B)
Engraftment assay of BM cells transduced with either MIGR1 or
MIGR-G0S2 retrovirus was analyzed after 15 h of i.v. injection
(n=3). *, P,0.05 (two-tailed Student’s t-test).
(TIF)
Figure S2 Cell cycle analysis of progenitor cells. LS
2K
cells were sorted from BM transplanted with MIGR1-G0S2 (A) or
pSIREN-shG0S2 (B), fixed in 70% ethanol, and stained with Ki67
and 7-AAD (n=3–5). *, P,0.05, and **, P,0.01 (two-tailed
Student’s t-test).
(TIF)
Figure S3 Ectopic expression of G0S2 inhibits pro-
liferation in EL4 cells and induced perinuclear seques-
tration of nucleolin in resting HSCs. (A) Cell growth was
analyzed in EL4 cells transduced with retroviruses MIGR1 or
MIGR1-G0S2 (n=3). **, P,0.01 (two-tailed Student’s t-test). (B)
Cell cycle analysis by DNA staining with propidium iodine. (C)
LSK CD150
+CD48
2 BM cells isolated from B6 and 5-FU-
injected B6 mice. Localization of nucleolin was determined by
immunofluorescence.
(TIF)
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